740 related articles for article (PubMed ID: 21504775)
21. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
22. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
[TBL] [Abstract][Full Text] [Related]
23. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
[TBL] [Abstract][Full Text] [Related]
24. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
25. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
26. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice.
Uchida M; Harada T; Enkhtuya J; Kusumoto A; Kobayashi Y; Chiba S; Shyaka A; Kawamoto K
Biochem Biophys Res Commun; 2012 May; 421(2):323-8. PubMed ID: 22507985
[TBL] [Abstract][Full Text] [Related]
27. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model.
Makam SS; Kingston JJ; Harischandra MS; Batra HV
Mol Immunol; 2014 May; 59(1):91-9. PubMed ID: 24513572
[TBL] [Abstract][Full Text] [Related]
28. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid.
Cui Z; Sloat BR
Int J Pharm; 2006 Jul; 317(2):187-91. PubMed ID: 16730934
[TBL] [Abstract][Full Text] [Related]
29. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
30. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
Sloat BR; Cui Z
Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
[TBL] [Abstract][Full Text] [Related]
31. Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.
Mamedov T; Chichester JA; Jones RM; Ghosh A; Coffin MV; Herschbach K; Prokhnevsky AI; Streatfield SJ; Yusibov V
PLoS One; 2016; 11(4):e0153956. PubMed ID: 27101370
[TBL] [Abstract][Full Text] [Related]
32. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
33. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
34. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
Front Immunol; 2018; 9():562. PubMed ID: 29616046
[TBL] [Abstract][Full Text] [Related]
35. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
[TBL] [Abstract][Full Text] [Related]
37. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH
PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820
[TBL] [Abstract][Full Text] [Related]
38. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
39. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Sloat BR; Shaker DS; Le UM; Cui Z
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
Williamson ED; Hodgson I; Walker NJ; Topping AW; Duchars MG; Mott JM; Estep J; Lebutt C; Flick-Smith HC; Jones HE; Li H; Quinn CP
Infect Immun; 2005 Sep; 73(9):5978-87. PubMed ID: 16113318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
